Themis Medicare
Themis Medicare Ltd valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Themis Medicare Ltd, framed against the sector median so the premium or discount is obvious at a glance.
Themis Medicare Ltd trades at a P/E of 866.58× and P/B of 2.54×.
Valuation
Profitability
Growth
Financial Health
Themis Medicare Ltd financials: P&L, balance sheet, cash flow, ratios.
Twelve years of audited numbers for Themis Medicare Ltd, switchable between annual and quarterly views, consolidated or standalone.
Themis Medicare Ltd reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹953.24 Cr and reported EPS of ₹0.12.
| Period | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 212 | 184 | 202 | 231 | 395 | 354 | 382 | 406 | 342 |
| Other Income | 3 | 3 | 3 | 4 | 7 | 12 | 5 | 5 | 9 |
| Total Income | 215 | 186 | 205 | 234 | 401 | 366 | 387 | 410 | 352 |
| Cost of Goods Sold (COGS) | 72 | 68 | 63 | 79 | 148 | 118 | 137 | 132 | 129 |
| Gross Profit | 140 | 115 | 138 | 152 | 246 | 236 | 245 | 274 | 213 |
| +Operating Expenses | 115 | 113 | 103 | 103 | 151 | 169 | 194 | 224 | 212 |
| EBITDA | 25 | 2 | 36 | 49 | 96 | 67 | 52 | 49 | 0 |
| +Non-Operating Expenses | 19 | 20 | 21 | 21 | 18 | 20 | 22 | 20 | 20 |
| Profit Before Tax (PBT) | 9 | -15 | 18 | 32 | 84 | 59 | 35 | 34 | -12 |
| +Tax Expense | 0 | -2 | 2 | 6 | 22 | 16 | 10 | 10 | 1 |
| Profit After Tax (PAT) | 11 | -11 | 25 | 36 | 73 | 57 | 44 | 30 | 1 |
| Earnings Per Share (EPS) | 1.23 | -1.17 | 2.70 | 3.89 | 7.92 | 6.18 | 4.73 | 3.24 | 0.12 |
| Diluted Shares Outstanding (Nos.) | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 |
| +Additional Disclosures | 280 | 272 | 259 | 290 | 476 | 438 | 507 | 514 | 506 |
| Sales Growth % | — | -13.20 | 9.71 | 14.43 | 71.07 | -10.21 | 7.74 | 6.22 | -15.60 |
| YoY Sales Growth % | — | -13.20 | 9.71 | 14.43 | 71.07 | -10.21 | 7.74 | 6.22 | -15.60 |
| Material Cost % | 25 | 27 | 25 | 29 | 29 | 27 | 22 | 19 | 17 |
| Employee Cost % | 21 | 25 | 22 | 17 | 13 | 19 | 22 | 24 | 27 |
| Other Cost % | 33 | 37 | 29 | 27 | 25 | 29 | 29 | 32 | 35 |
| OPM % | 12 | 1 | 18 | 21 | 24 | 19 | 13 | 12 | 0 |
| Tax % | 1 | 12 | 12 | 18 | 27 | 27 | 29 | 29 | -6 |
| Profit Growth % | — | -195.78 | 330.32 | 44.07 | 104.13 | -21.93 | -23.51 | -31.46 | -96.17 |
| Gross Margin % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA Margin % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | -0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.00 |
| Additional Fields | 18 | -6 | 27 | 41 | 86 | 57 | 39 | 39 | -10 |
Themis Medicare segment analysis: revenue and profit mix.
Disclosed business segments at Themis Medicare with their share of revenue and profit, switchable between consolidated and standalone reporting.
Themis Medicare discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
Themis Medicare Ltd investment thesis: bull case, bear case, and the flip lines.
Why someone would buy Themis Medicare Ltd, why someone wouldn't, and the quantitative tripwires that would force the call to flip.
Themis Medicare Ltd's investment case rests on 9 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Strong promoter confidence with substantial 67.2% holding indicates long-term commitment.
Healthy balance sheet reflected by a low 0.21 debt-to-equity ratio.
Diverse product portfolio spanning multiple therapeutic areas, including critical care.
Long-standing presence since 1952 provides significant industry experience and connections.
Positive 5-year revenue growth of 15.00% demonstrates historical expansion.
What can break it.
Reported significant net loss of -14.2 Cr, with quarterly profit declining -158%.
Latest quarterly sales dropped by -20.70%, indicating substantial revenue contraction.
Poor profitability. negative EPS (-0.98), P/E 0.00, and very low OPM.
Subpar return ratios. ROCE 10.40% and ROE 7.65% are below peers.
Current price significantly below 52-week high, reflecting negative investor sentiment.
What would change my mind.
Trim if P/E re-rates above 1127. The valuation cushion thins from there.
Reassess if quarterly profit growth prints below 0% for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 25.61. Balance sheet risk re-prices growth multiples fast.
Exit if ROE slips below 8%. The operating engine is no longer compounding capital efficiently.
Themis Medicare Ltd peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Themis Medicare Ltd is highlighted for quick read-across.
Quick Compare
Peer Comparison
Themis Medicare Ltd technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Themis Medicare Ltd — derived from the live tape, not yesterday's close.
Themis Medicare Ltd last traded at ₹103.99 with an intraday range of ₹101–₹104.97 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹103.99| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 113.58 | +9.59 | +9.22% |
| R3 | 109.61 | +5.62 | +5.40% |
| R2 | 107.29 | +3.30 | +3.17% |
| R1 | 105.64 | +1.65 | +1.59% |
| PIVOT | 103.32 | -0.67 | -0.64% |
| CURRENT | 103.99 | — | — |
| S1 | 93.73 | -10.26 | -9.87% |
| S2 | 97.70 | -6.29 | -6.05% |
| S3 | 99.35 | -4.64 | -4.46% |
| S4 | 101.67 | -2.32 | -2.23% |
THEMISMED is trading Above CPR, indicating Bullishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: 101 ~ 103.75
Trading Above opening range, showing Bullishness
Themis Medicare Ltd delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Themis Medicare Ltd over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Themis Medicare Ltd stood at 35.6% of traded volume, against a 20-day average of 47.8%.
Themis Medicare announcements: results, concalls, ratings, M&A.
Filings Themis Medicare sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Themis Medicare files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 56 documents below.
Copy of Newspaper Publication
Themis Medicare Limited has informed the Exchange about Copy of Newspaper Publication
Investor Presentation
Themis Medicare Limited has informed the Exchange about Investor Presentation
Outcome of Board Meeting
Themis Medicare Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
Copy of Newspaper Publication
Themis Medicare Limited has informed the Exchange about Copy of Newspaper Publication
Disclosure under SEBI Takeover Regulations
Dr. Dinesh S. Patel has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India…
Investor decks & rating reports.
Themis Medicare dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Themis Medicare has declared, sequenced by announce and record date.
Themis Medicare corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Themis Medicare Ltd: business, sector, key facts.
What Themis Medicare Ltd does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Themis Medicare Ltd operates in the Healthcare, listed as NSE: THEMISMED, BSE: 530199.
Themis Medicare Limited is a pharmaceutical company with a significant presence in India and international markets. Its core business revolves around the manufacture and sale of pharmaceutical products, encompassing both Active Pharmaceutical Ingredients (APIs) and finished formulations. This broad portfolio allows them to cater to a wide range of therapeutic needs.
The company's product offerings span numerous therapeutic areas, reflecting a diverse and comprehensive approach to pharmaceutical development and distribution. Key therapeutic categories include anti-tuberculosis and anti-malarial medications, addressing significant global health challenges. They also produce formulations for cardiology, pain management, and anti-infectives, demonstrating a focus on common and critical health concerns.
Furthermore, Themis Medicare's product line extends to haematinics (agents that increase red blood cell production), health and nutrition supplements, anaesthetics, gynaecological medications, and orthopedic pharmaceuticals. This extensive range indicates a commitment to providing a wide array of solutions across diverse medical specialties. The inclusion of anti-inflammatory drugs further broadens their reach within the common therapeutic landscape.
Established in 1952 and headquartered in Mumbai, India, Themis Medicare Limited has a long history within the pharmaceutical industry. Initially known as Themis Chemicals, the company rebranded to its current name in 2001, reflecting its evolution and growth. Their long-standing presence in the market suggests a significant level of experience and established industry connections.
Questions investors ask about Themis Medicare Ltd (THEMISMED).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Themis Medicare Ltd (THEMISMED)?
The current share price of Themis Medicare Ltd (THEMISMED) is ₹103.99. Today, the stock has gained by ₹3.68 (3.67%), trading in a range of ₹101 to ₹104.97. The stock opened at ₹101 with a trading volume of 38,400 shares.
02Is Themis Medicare Ltd stock a good investment for long-term?
Themis Medicare Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹953.24 crores, P/E ratio of 866.58, ROE of 0.29%, and ROCE of 10.40%. The dividend yield stands at 0.50%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Themis Medicare Ltd stock?
The 52-week high price of Themis Medicare Ltd (THEMISMED) is ₹0, while the 52-week low is ₹0. Currently trading at ₹103.99, the stock is Infinity% away from its 52-week low and -Infinity% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Themis Medicare Ltd stock at the current price?
Whether to buy Themis Medicare Ltd stock at ₹103.99 depends on multiple factors. The stock is currently trading with a P/E ratio of 866.58 and P/B ratio of 2.54. Today's performance shows a gain of 3.67%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Themis Medicare Ltd and when is the next dividend?
Themis Medicare Ltd offers a dividend yield of 0.50%, which means for every ₹100 invested at the current price of ₹103.99, you can expect to receive approximately ₹0.50 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Themis Medicare Ltd?
Themis Medicare Ltd's key financial metrics include: P/E Ratio: 866.58, P/B Ratio: 2.54, ROE: 0.29%, ROCE: 10.40%, Dividend Yield: 0.50%, EPS: ₹0.12, Book Value: ₹40.99, and Debt-to-Equity: 25.11. The company's market cap stands at ₹953.24 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Themis Medicare Ltd stock performing today in the market?
Themis Medicare Ltd stock opened at ₹101 and is currently trading at ₹103.99, showing a gain of ₹3.68 (3.67%). The intraday high is ₹104.97 and low is ₹101. The trading volume stands at 38,400 shares, indicating moderate market participation today.
08What is the P/E ratio of Themis Medicare Ltd and what does it indicate?
Themis Medicare Ltd has a Price-to-Earnings (P/E) ratio of 866.58, which means investors are willing to pay ₹866.58 for every ₹1 of earnings. With an EPS of ₹0.12, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Themis Medicare Ltd (THEMISMED) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs & Pharmaceuticals (AKUMS) Share PricePeer
- Top Gainers TodayScreener
- Other overvalued NSE stocksScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy